title: Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research.
abstract: OBJECTIVE
  This study seeks to improve the understanding of treatment patterns and associated health-related quality of life (HRQoL), clinical outcomes and healthcare utilization in US patients with castration-resistant prostate cancer (CRPC).
  
  
  METHODS
  Treatment Registry for Outcomes in CRPC Patients (TRUMPET) is a US-based, prospective, observational multicenter registry (NCT02380274) involving patients with CRPC and their caregivers. Patients initiating their first active treatment course will be enrolled from urology and medical oncology practices, with data captured up to 4 years.
  
  
  RESULTS
  Information on prescribing patterns, HRQoL, clinical outcomes and healthcare utilization will be collected.
  
  
  CONCLUSIONS
  TRUMPET will enable scientific understanding of disease management in terms of HRQoL, clinical outcomes and healthcare utilization in clinical practice for patients with CRPC.
authors.affiliation: Vanderbilt University Medical Center, Nashville, TN, USA.
authors.forename: David F
authors.initials: DF
authors.lastname: Penson
authors.affiliation: University of Washington, Seattle, WA, USA.
authors.forename: Daniel W
authors.initials: DW
authors.lastname: Lin
authors.affiliation: The Urology Center of Colorado, Denver, CO, USA.
authors.forename: Lawrence
authors.initials: L
authors.lastname: Karsh
authors.affiliation: USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
authors.forename: David I
authors.initials: DI
authors.lastname: Quinn
authors.affiliation: North Shore University Health System, Evanston, IL, USA.
authors.forename: Daniel H
authors.initials: DH
authors.lastname: Shevrin
authors.affiliation: Carolina Urologic Research Center, Myrtle Beach, SC, USA.
authors.forename: Neal
authors.initials: N
authors.lastname: Shore
authors.affiliation: Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA.
authors.forename: James T
authors.initials: JT
authors.lastname: Symanowski
authors.affiliation: Astellas Pharma, Inc., Northbrook, IL, USA.
authors.forename: Bruce
authors.initials: B
authors.lastname: Brown
authors.affiliation: Medivation, Inc., San Francisco, CA, USA.
authors.forename: David
authors.initials: D
authors.lastname: Forer
authors.affiliation: Medivation, Inc., San Francisco, CA, USA.
authors.forename: Elaine K
authors.initials: EK
authors.lastname: Wong
authors.affiliation: Astellas Pharma, Inc., Northbrook, IL, USA.
authors.forename: Scott C
authors.initials: SC
authors.lastname: Flanders
mesh_terms: D017028:Caregivers; D019468:Disease Management; D017048:Health Care Costs; D019538:Health Care Surveys; D006801:Humans; D008297:Male; D010342:Patient Acceptance of Health Care; D017060:Patient Satisfaction; D064129:Prostatic Neoplasms, Castration-Resistant / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D012042:Registries; D012106:Research; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
keywords: castration-resistant prostate cancer; health-related quality of life; treatment utilization